



# Euro BioFairs Compass

2<sup>nd</sup> Edition 2021

## II Guide to Life Sciences Events



# Let's save the planet!



## Join the European Biotechnology Network!

COVID-19, climate apocalypse, billions of people in turmoil. New strategies are desperately needed. Biotechnology creates confidence and solutions. The European Biotechnology Network is a non-profit organisation that aims to facilitate cooperation between all professionals in biotechnology and life sciences on the European continent.

**Find out about (free) membership on our website [www.european-biotechnology.net](http://www.european-biotechnology.net)**

©master24 - stock.adobe.com

**European Biotechnology Network AISBL**  
Rue de la Science 14b | 1040 Brussels  
Belgium | Tel: +32 (0)2 588 70 71  
[www.european-biotechnology.net](http://www.european-biotechnology.net)  
[info@european-biotechnology.net](mailto:info@european-biotechnology.net)

- 
- ANDVARI ALVA
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 

CORPORATE MEMBERS 1/21



# Digital events across Europe

**EUROBIOFAIRS COMPASS** Meeting the own individual, specific network digitally may feel challenging in times of COVID-19. However, as vaccination rates progress, some events try to come back in a hybrid format that offers the opportunity to meet potential new partners in person. In any case, Euro BioFair's Compass will help you navigate the European meeting jungle in H2/2021.

The biggest difficulty of professional events that have quickly developed digital formats is currently planning. Because at the moment it is simply not possible to reliably predict if and when travel and meetings will be possible again in the usual form. The earlier the event date, the greater the tendency to revert to the digital format.

## Booming biotech

This is also the case with the 2021 summer edition of the **AMR conference** (24–26 August 2021) hosted digitally by BIOCOM in cooperation with European SME organisation BEAM Alliance.

The digital three-day conference will shed light on the most recent developments in the field of antimicrobial resistance (AMR). According to a brand-new WHO report, the static pipeline with only few antibiotics being approved by regulatory agencies in recent years remains a reality as payors are not pre-

pared to pay appropriate prices that would compensate for the development risks. Speakers at the conference will give an update about projects funded by the global accelerator network CARB-X, the EU-funded IMI AMR accelerator, the Novo Repair Impact Fund and the AMR Action Fund. A special focus of the event remains on the perspective of innovative SMEs.

The market-leading annual event in Europe for Industrial Biotechnology and the Bioeconomy, the **EFIB**, hopefully will return this year (6–7 October, 2021) with the very first in-person conference to Vienna. EuropaBio, together with LISAvienna as local host, invite stakeholders to learn about Austria's bioeconomy strategy. Focus areas include novel bio-based materials for packaging, textiles and for the building sector, sustainable financing and green architecture as well as innovative food and feed solutions in the area of cell-based and plant-based products.

One of the leading biotechnology conferences in Europe also tries to return to the stage: On September 7, 2021 the **Swiss Biotech Day** (SBD) will offer networking opportunities with expected 500 biotech leaders and an update on the most recent trends in Switzerland's biotech and investment ecosystem. The SBD includes an all-day exhibition, keynote speeches, company presentations, panel discussions and a 1:1 partnering platform.

More than 1,000 international players composed of TTOs, research institutes, incubators and academia together with pharma, biotech and diagnostic companies, veterinary firms and pre-seed/seed/Series A investors are expected to visit the **BioFIT 2021** (7–9 December 2021), the leading partnering event in Europe for technology transfer, academia-industry collaborations, early-stage innovation deals and the European marketplace for early-stage financing rounds in the Life Sciences field. ■



**BIOCOM**®



**24 – 26 August 2021**  
Delivered digitally

# AMR after COVID-19

**AMR CONFERENCE 2021** The summer edition of the 5<sup>th</sup> AMR Conference will provide a platform to discuss the current state of the fight against antimicrobial resistance (AMR). The agenda will be driven by updates of investors, lessons learned from COVID-19, the presentation of new initiatives and insights on the current status of pull incentives.

Being an established platform to connect relevant AMR stakeholders from industry, SMEs, finance, hospitals, science, and policy, the fifth AMR Conference will offer three afternoons of virtual AMR briefing sessions on the most urgent topics, the AMR community is

## › QUICK FACTS

- › **Day 1 – Status quo & Covid Impact:** What has changed after one year of COVID-19?
- › **Day 2 – Financing & Investing:** What's new with funds, incubators and accelerators
- › **Day 3 – Policy & Incentives:** What can we learn from best practices to go ahead?

[www.amr-conference.com](http://www.amr-conference.com)

currently discussing: Did the COVID-19 pandemic change perceptions on the relevance and urgency of antimicrobial resistance and will new infrastructures for pandemic preparedness have an impact on dealing with AMR? Which new initiatives have been started to further push forward innovations in antimicrobial therapies and diagnostics? What updates can be provided by existing investors, funds and accelerators? How did policymakers in Europe and the US take over their role in establishing most needed pull incentives and what can be summarized by the first pilot running in the UK?

The 2021 summer edition of the conference, hosted by BIOCOM in cooperation with the European SME organisation BEAM Alliance, will shed light on the most recent developments in 2021. On the one hand, novel reports such as the annual antibacterial pipeline re-

port by the World Health Organization (WHO), published in April, clearly show the still high need for novel antibiotics. According to the review, there is a near static pipeline with only few antibiotics being approved by regulatory agencies in recent years. On the other hand, major investments have pushed forward R&D in novel approaches across the globe. During the conference the global accelerator network CARB-X will summarize its achievements over the past five years, the EU-funded IMI AMR Accelerator is summarizing its first year of activities and a new incubator initiative in Europe is presenting. Investors such as the Novo Repair Impact Fund and the AMR Action Fund are looking back on 2021, and policymakers are updating on novel reimbursement schemes.

A special focus of the event remains on the perspective of innovative SMEs. "2021 will be a decisive year for many of us", predicts Marc Gitzinger, Vice President of the BEAM Alliance and CEO of Swiss BioVersys. Whereas some companies recently managed to attract large rounds of financing, others might be forced to either down-size or close their AMR pipeline. According to Gitzinger and his CEO colleagues, investors are becoming nervous, because governments are not ambitious enough to implement adequate pull incentives now: "We hope that policymakers learned the COVID-19 lessons."



24–26  
August  
**2021**  
Delivered digitally

# 5<sup>th</sup> AMR Conference

## Summer Edition | AMR Briefing Sessions

International AMR experts from industry, SMEs, start-ups, big pharma, academia, clinics, regulatory bodies, investors, public institutions and policy will meet virtually at the **5<sup>th</sup> AMR Conference – Summer Edition** to provide an update on major trends and developments on policy incentives, financing and new initiatives to bring **novel antimicrobial treatments to the market**. We will particularly discuss how Europe can play a role in the fight against AMR in the post COVID-19 time period.

Each day will bring together **LIVE speakers and high level panels** within an **AMR briefing session from 2pm to 4 pm**:

- › **Day 1:** Status quo & COVID-19 Impact: What has changed after one year of COVID?
- › **Day 2:** Financing & Investing: What's new with funds, incubators and accelerators?
- › **Day 3:** Policy & Incentives: What can we learn from best practices to go ahead?

Save the date &  
join us in summer!

**amr-conference.com**  
**#AMRconference**

We are part of the  
**#GlobalAMRChallenge**



# SWISS BIOTECH™

September 7, 2021  
Congress Center Basel,  
Switzerland

## Biotech live

**SWISS BIOTECH DAY** One of the leading biotechnology conferences in Europe is back on stage: On September 7, 2021, the event offers networking opportunities and an inspiring programme.

In 2019 the event took place in Basel with more than 850 participants from 25 countries. This record-breaking attendance confirmed the leading role of the Swiss Biotech Day as an industry networking platform. Few regions can compete with the density and variety of biotech stakeholders and their international partners gathered in Basel. While the Swiss Biotech Day could not take place in 2020 due to the COVID-19 pandemic, it is planned to bring it back on stage on September 7, 2021.

Participants can expect to meet over 500 senior experts from the life science industry from across Europe and delegations from various countries. The conference includes an all-day exhibition, keynote speeches, company presentations, panel discussions and a 1:1 partnering platform. The plenary session will also include the award ceremony of the Swiss Biotech Success Stories.

The Swiss Biotech Day covers the entire value chain, from cutting-edge research and smart development to effi-

cient manufacturing. It attracts biotech entrepreneurs, investors, researchers, analysts, political decision-makers, and industry stakeholders alike. The event's inspiring programme with thematically focused panel discussions allows plenty of time for networking. An emphasis will lie on opportunities and synergies offered by the close collaboration of pharma and biotech in the post-Covid era. Platforms will be provided to discuss trends in research and development, production, data management, artificial intelligence, and innovative financing.

With pre-scheduled partnering talks in a private setting, and presentations of emerging and clinical-stage companies, the Swiss Biotech Day will be as multifaceted as the life sciences industry itself. ■

## We are back!



**GREETING** For more than a year we have been locked down, working from our home offices and we now know how to meet and greet virtually in all shapes and forms. The biotech and pharma industries have worked hand in hand to rapidly develop solutions to mitigate

*the impact of COVID-19 and the efficacious vaccines will finally lead the way out of this pandemic.*

*Now it is time to meet again in person! We look forward to welcoming you in Basel. To take advantage of the side talks at the coffee machine, to enjoy the apéro, to shake hands and to finally see friends and business partners in real live again!*

**Michael Altorfer**  
CEO, Swiss Biotech Association

## QUICK FACTS

### REGISTRATION

[www.swissbiotechday.ch](http://www.swissbiotechday.ch)  
Phone: +41-43-508-11 21  
[register@swissbiotechday.ch](mailto:register@swissbiotechday.ch)

### Highlights

- › Swiss Biotech Success Stories Awards
- › Innovative biotech start-ups and medium-sized biotech companies
- › Thematically focused panel discussions
- › one-to-one partnering meetings

**Save the date!**

# SWISS BIOTECH DAY

© Swiss Biotech Association



**7 Sep 2021**  
Congress Center Basel


The Swiss Biotech Day has become one of the leading biotechnology conferences in Europe and is a fixed date in the community's calendar. While the event could not take place in 2020 due to the worldwide COVID-19 pandemic, we plan to bring the Swiss Biotech Day back on stage on 7 September 2021. We would love to meet you all in person again.

Sign in on our website at  
[www.swissbiotechday.ch](http://www.swissbiotechday.ch)  
and we will inform you about any news.

Sponsors:



Supporting partners:



Media partners:



Organized by:





6 – 7 October, 2021  
Vienna, Austria

# Back face-to-face

**EFIB 2021** About 400 attendees are expected to join the 14<sup>th</sup> edition of the “European Forum for Industrial Biotechnology and the Bioeconomy” (EFIB) in Vienna, Austria. The two-day event will discuss industrial contributions towards a smarter, more sustainable circular bioeconomy in areas such as food, materials and bioprocesses.

A year and a half after the Green Deal publication by the European Commission in December 2019, the EFIB conference will take stock of achievements made: How can Europe reach its goal to be among the global leaders of sustainable innovation? Which strategies are pursued by corporates and SMEs to apply transformative bio-based technologies? With the 14th edition of EFIB, EuropaBio will, together with LISAVienna as local

host, invite stakeholders to join for one of the first in-person conferences in the industrial biotech and bioeconomy sector for 2021. This year also marks EuropaBio’s 25th anniversary and the event will see the launch of an “EFIB Vienna statement” on priorities and vision for industrial biotechnology.

Under the main theme “Delivering the EU Green Deal: Industrial biotechnology into business”, the EFIB 2021 program

features 10+ focused plenary and parallel tracks as well as roundtable sessions, attracting about 70+ speakers across the two main conference days to shed light on business and innovation strategies, technology challenges and policy frameworks.

Focus areas include novel bio-based materials for packaging, textiles and for the building sector, sustainable financing and green architecture as well as innovative food and feed solutions in the area of cell-based and plant-based products. As local host, Austrian capital Vienna will particularly highlight its competences in the field of industrial biotechnology and sustainable circular bioeconomy.

## Special invitation to start-ups

EFIB offers a reduced fee for SMEs as well as for academics. Start-ups are invited to apply for free booth space in the Start-up Village until 16 June. ■

## EU Green Deal



**GREETING** With the European Green Deal, the EU has set an ambitious strategy towards climate neutrality and a more

circular economy, and sustainable innovation has gained momentum. The 14th edition of Europa-

*Bio’s annual EFIB conference will gather stakeholders from science, industry, finance, and policy to raise awareness of bio-based innovations and discuss potentials as well as challenges that remain. We are very pleased that #EFIB2021 is hosted in Vienna, which is a hotspot for smart and sustainable solutions for cities and an advanced city when it comes to sustainable technologies and innovation projects. We hope you will join us! at #EFIB2021*

**Agnes Borg,**  
Industrial Biotech, Director, EuropaBio

## QUICK FACTS

### Highlights

- 70+ speakers in 10+ plenary, parallel tracks and roundtables
- Exhibition and 1:1 partnering
- Pre-conference workshop
- 20 innovative founders in the Start-up Village
- Special fees for SMEs/ academics
- Release of EuropaBio’s “Vienna Statement”
- [www.efibforum.com](http://www.efibforum.com)



14<sup>th</sup> Annual

# EFIB 2021

The European Forum for Industrial  
Biotechnology and the Bioeconomy

Organised by



The European Association for Bioindustries

## EUROPE'S LEADING EVENT ON INDUSTRIAL BIOTECHNOLOGY AND THE BIOECONOMY

6 – 7 October 2021 · Vienna · Austria

### Delivering the EU Green Deal: from industrial biotechnology to business

Save the date to meet experts in industrial biotechnology and bioeconomy after a long time of event bans due to COVID-19. Network with your peers and gain insights into innovative solutions to create a healthy and sustainable planet.

#### Register now

and save 350 € with our  
super early bird rate

**Deadline: 10 June 2021**

#### Start-ups wanted

Apply for a free space in the  
Start-up Village

**Deadline: 16 June 2021**

Supporting Partner

**BIOCOM**

Local Partner

**LISA**vienna  
life science austria

Sponsors

**DSM**  
BRIGHT SCIENCE. BRIGHTER LIVING.

**PAN**  
BIOTECH

**TWIST**  
BIOSCIENCE

**BUSINESS**  
**FINLAND**



If you are interested in taking part, please contact:  
Nathalie Di Napoli · [n.dinapoli@biocom.de](mailto:n.dinapoli@biocom.de)

[www.efibforum.com](http://www.efibforum.com)



7 – 9 December 2021  
Digital Format  
European Standard Time

# Sourcing innovations

**BIOFIT** BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer, early-stage innovation deals and pre-seed, seed and Series A investment rounds in Life Sciences by welcoming 1,000+ delegates from 35+ countries.

With 1,000+ international players composed of TTOs, research institutes, incubators and academia together with pharma, biotech and diagnostic companies, veterinary firms and pre-seed/seed/Series A investors, BioFIT has become the leading partnering event in Europe for technology transfer, academia-industry collaborations, early-stage innovation deals and the European marketplace for early-stage financing rounds in the Life Sciences field. The event is above

all an optimal business convention with prequalified one-on-one meetings. Its online platform allows participants to identify potential partners, to pre-schedule meetings and to meet them during the event in order to build partnerships. During the last edition, 6,000+ meetings have been generated through the partnering system. The BioFIT business convention offers, in addition to the one-on-one meetings, a conference programme steered by a prestigious committee. The

2021 programme is rooted in four custom-made tracks, addressing the right funding sources for early-stage innovation, best practices in academia-industry R&D collaborations, winning ways to nurture early-stage assets and last animal health highlights. The BioFIT pitch sessions give the opportunity to detect the most innovative start-ups and the most promising collaborative and licensing opportunities to foster partnerships and business development in the Life Sciences field. It is a great opportunity for bioentrepreneurs to showcase their project or assets in front of potential partners: The Start-up Slams are dedicated to young companies seeking to raise a pre-seed, seed or Series A financing round and the Collaborative and Licensing Opportunity Presentations are devoted to TTOs, universities, research institutes and companies willing to promote an early-stage asset to find out licensing or collaborative project deals. ■

## Welcome to BioFIT



**GREETING** Since its first edition, in 2010, BioFIT has become the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field. Based on the past two editions, we observe out of 1,000+ BioFIT attendees, 1,015+ deals have been generated, of which 35% are collaborative research projects, 30% licensing deals, 15% equity

*investment deals and 20% service deals. We would be very pleased to welcome you from December 7th to 9th, 2021 in a digital format for the 10th edition of BioFIT, which provides the ideal environment for academia and industry actors to build partnerships, to source innovative and competitive early-stage R&D projects, to facilitate the emergence of collaborative projects, to increase licensing opportunities and to obtain funding.*

**Etienne Vervaecke**  
General Manager  
Eurasanté & Clubster NHL

## QUICK FACTS

### Key figures

1,000+ delegates | 40+ speakers  
35+ countries represented  
6,000+ one-on-one meetings

### Inside the event

➤ One-on-one meetings | Exhibition  
| Conferences | Pitch sessions

### Registration & contact

[www.biofit-event.com](http://www.biofit-event.com)  
[letsibah@eurasante.com](mailto:letsibah@eurasante.com)



**Biofit** FOSTERING  
INNOVATION  
& TRANSFER

The leading European partnering event  
for early-stage innovation deals  
and investment rounds  
in the field of **Life Sciences**

**DIGITAL  
FORMAT**

**DECEMBER  
7<sup>TH</sup> – 9<sup>TH</sup>  
2021**

**10<sup>TH</sup> EDITION**



**1,000+  
delegates**



**35+ countries  
represented**

### INSIDE THE EVENT:

- **One-on-one meetings**
- **Conferences**
- **Pitch sessions**
- **Exhibition**

**ORGANISED  
TOGETHER WITH**

**MedFIT**  
Fostering Innovation in medTech

Medtech, Diagnostic & Digital Health

2021 Sponsors:



Organisers: